Pfizer Inc (PFE) Com Stk USD0.05 (CDI)
$0.0641
(0.26%)
- Add to watchlist
- This stock can be held in a
$0.0641
(0.26%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.0641
(0.26%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Pfizer lifts full-year guidance on bumper Q3 sales
29 October 2024 11:11
(Sharecast News) - Pfizer lifted its full-year guidance on Tuesday after third-quarter numbers beat Wall Street expectations.
-
Pfizer lifts outlook on strong Q2 sales
30 July 2024 12:35
(Sharecast News) - US pharma giant Pfizer lifted its full-year profit forecast on Tuesday after second-quarter sales of its Covid vaccine and antiviral treatment came in better than expected, along with...
-
Pfizer ups full-year earnings outlook
1 May 2024 12:12
(Sharecast News) - Pfizer raised its full-year earnings forecast on Wednesday, on the back of solid demand for its non-Covid products.
-
Pfizer sells bigger-than-expected stake in Haleon
19 March 2024 09:39
(Sharecast News) - Haleon said on Tuesday that Pfizer has sold a larger-than-expected stake in the consumer healthcare group, taking its interest down to 22.6% from 32%.
-
Pfizer to cut stake in Haleon to 24% from 32%
18 March 2024 07:35
(Sharecast News) - Consumer healthcare company Haleon said on Monday that Pfizer plans to sell around 630m shares in the company in a public offering.
-
Pfizer posts better-than-expected Q4 results
30 January 2024 12:02
(Sharecast News) - Pharmaceutical giant Pfizer reported better-than-expected quarterly earnings on Tuesday, driven by its cost-cutting programme aimed at an eventual return to profitability.
-
Pfizer shares slump 10% as annual outlook cut
13 December 2023 12:04
(Sharecast News) - Shares in Pfizer slumped on Wednesday as the US drugs giant said annual revenue and profit would come in below expectations.
-
Pfizer gets all regulatory approvals to close $43bn Seagen deal
12 December 2023 12:56
(Sharecast News) - Pfizer said on Tuesday that it has now received all regulatory approvals needed to close its $43bn acquisition of Seagen after agreeing to donate the rights of royalties from sales of its...
-
Roughly 500 jobs to go at Pfizer's Kent site
14 November 2023 16:00
(Sharecast News) - Around 500 jobs are set to go at pharma giant Pfizer's Kent site.
-
Pfizer posts first quarterly loss since 2019
31 October 2023 12:13
(Sharecast News) - Drugmaker Pfizer posted third-quarter sales that missed estimates and reported its first quarterly loss since 2019 on Tuesday amid plummeting demand for its Covid-19 vaccine.
-
Roche strikes $7.1bn deal to buy Telavant
23 October 2023 09:38
(Sharecast News) - Swiss drug giant Roche has agreed to buy Telavant Holdings from Pfizer and Roivant Sciences in a $7.1bn deal, it was announced on Monday.
-
GSK settles California Zantac lawsuit
11 October 2023 11:51
(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.
Company announcements Announcements
No company announcements about Pfizer Inc Com Stk USD0.05 (CDI) were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.